
OZM-101 | NeoPancOne
NCT04472910
Pending
GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma (NeoPancOne)
Status:
Opening Soon

II
Phase

Neoadjuvant
Line of Therapy

Early Cancer
Disease Stage

Biomarker(s)
N/A
Investigational
Product
Modified Folforinox (mFFX)
Treatment Arms
Single Group Assignment:
Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy